Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma

NCT02248805 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT02248805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02248805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 DART® Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2014
Completion date
July 2, 2018
Enrollment
95 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma